Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more
Biotechnology Assets S.A. (BST) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.102x
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has a cash flow conversion efficiency ratio of 0.102x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€658.13K) by net assets (€6.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotechnology Assets S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Biotechnology Assets S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biotechnology Assets S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotechnology Assets S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manaksia Limited
NSE:MANAKSIA
|
-0.039x |
|
Sino Logistics Corporation Public Company Limited
BK:SINO
|
0.046x |
|
Knight Club Capital Asset Management PCL
BK:KCC
|
0.062x |
|
ADM Hamburg Aktiengesellschaft
F:OEL
|
0.392x |
|
Dignitana AB (publ.)
PINK:DIZTF
|
-0.115x |
|
HSS HIRE GROUP LS -01
F:HG3
|
N/A |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
-0.001x |
|
PSS EXOL SA D ZY 1
F:9B2
|
N/A |
Annual Cash Flow Conversion Efficiency for Biotechnology Assets S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €6.61 Million | €-73.85K | -0.011x | -252.87% |
| 2023-12-31 | €6.53 Million | €47.74K | 0.007x | +101.63% |
| 2022-12-31 | €3.87 Million | €-1.73 Million | -0.447x | -29.25% |
| 2021-12-31 | €4.34 Million | €-1.50 Million | -0.346x | -115.13% |
| 2020-12-31 | €3.84 Million | €8.79 Million | 2.288x | +214.10% |
| 2019-12-31 | €7.56 Million | €-15.16 Million | -2.005x | -226.35% |
| 2018-12-31 | €21.19 Million | €-13.02 Million | -0.614x | -2410.54% |
| 2017-12-31 | €8.03 Million | €213.49K | 0.027x | -92.21% |
| 2016-12-31 | €7.96 Million | €2.71 Million | 0.341x | +1533.30% |
| 2015-12-31 | €7.57 Million | €158.16K | 0.021x | +152.79% |
| 2014-12-31 | €7.68 Million | €-303.79K | -0.040x | -- |